JP2013538829A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013538829A5 JP2013538829A5 JP2013530333A JP2013530333A JP2013538829A5 JP 2013538829 A5 JP2013538829 A5 JP 2013538829A5 JP 2013530333 A JP2013530333 A JP 2013530333A JP 2013530333 A JP2013530333 A JP 2013530333A JP 2013538829 A5 JP2013538829 A5 JP 2013538829A5
- Authority
- JP
- Japan
- Prior art keywords
- agent
- targeted delivery
- conjugate
- group
- nanocarrier
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims description 71
- 239000002539 nanocarrier Substances 0.000 claims description 42
- 239000003795 chemical substances by application Substances 0.000 claims description 36
- 239000000032 diagnostic agent Substances 0.000 claims description 32
- 229940039227 diagnostic agent Drugs 0.000 claims description 28
- 238000000034 method Methods 0.000 claims description 28
- 239000003814 drug Substances 0.000 claims description 17
- 229940124597 therapeutic agent Drugs 0.000 claims description 17
- 108091023037 Aptamer Proteins 0.000 claims description 14
- 150000002632 lipids Chemical class 0.000 claims description 14
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 12
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 12
- 125000005647 linker group Chemical group 0.000 claims description 12
- 102000005962 receptors Human genes 0.000 claims description 12
- 108020003175 receptors Proteins 0.000 claims description 12
- 230000008685 targeting Effects 0.000 claims description 12
- 239000002502 liposome Substances 0.000 claims description 10
- 230000001225 therapeutic effect Effects 0.000 claims description 9
- BEVWMRQFVUOPJT-UHFFFAOYSA-N 2,4-dimethyl-1,3-thiazole-5-carboxamide Chemical compound CC1=NC(C)=C(C(N)=O)S1 BEVWMRQFVUOPJT-UHFFFAOYSA-N 0.000 claims description 8
- 229910019142 PO4 Inorganic materials 0.000 claims description 8
- UWHCKJMYHZGTIT-UHFFFAOYSA-N Tetraethylene glycol, Natural products OCCOCCOCCOCCO UWHCKJMYHZGTIT-UHFFFAOYSA-N 0.000 claims description 8
- 239000002246 antineoplastic agent Substances 0.000 claims description 8
- 239000002872 contrast media Substances 0.000 claims description 8
- IIRDTKBZINWQAW-UHFFFAOYSA-N hexaethylene glycol Chemical compound OCCOCCOCCOCCOCCOCCO IIRDTKBZINWQAW-UHFFFAOYSA-N 0.000 claims description 8
- GLZWNFNQMJAZGY-UHFFFAOYSA-N octaethylene glycol Chemical compound OCCOCCOCCOCCOCCOCCOCCOCCO GLZWNFNQMJAZGY-UHFFFAOYSA-N 0.000 claims description 8
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 claims description 8
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 8
- 239000010452 phosphate Substances 0.000 claims description 8
- 230000002285 radioactive effect Effects 0.000 claims description 8
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims description 8
- ZIBGPFATKBEMQZ-UHFFFAOYSA-N triethylene glycol Chemical compound OCCOCCOCCO ZIBGPFATKBEMQZ-UHFFFAOYSA-N 0.000 claims description 8
- 102100036301 C-C chemokine receptor type 7 Human genes 0.000 claims description 6
- 102000004161 Claudin-4 Human genes 0.000 claims description 6
- 108090000601 Claudin-4 Proteins 0.000 claims description 6
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 6
- 229930186217 Glycolipid Natural products 0.000 claims description 6
- 101000716065 Homo sapiens C-C chemokine receptor type 7 Proteins 0.000 claims description 6
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 claims description 6
- 108010008707 Mucin-1 Proteins 0.000 claims description 6
- 102100034256 Mucin-1 Human genes 0.000 claims description 6
- 108010008699 Mucin-4 Proteins 0.000 claims description 6
- 102100022693 Mucin-4 Human genes 0.000 claims description 6
- 102100021010 Nucleolin Human genes 0.000 claims description 6
- 108700020796 Oncogene Proteins 0.000 claims description 6
- 108091000080 Phosphotransferase Proteins 0.000 claims description 6
- 102000008858 Somatostatin receptor 4 Human genes 0.000 claims description 6
- 229940123237 Taxane Drugs 0.000 claims description 6
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 6
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 6
- 208000021841 acute erythroid leukemia Diseases 0.000 claims description 6
- 229960004562 carboplatin Drugs 0.000 claims description 6
- 190000008236 carboplatin Chemical compound 0.000 claims description 6
- 235000012000 cholesterol Nutrition 0.000 claims description 6
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 6
- 229960004316 cisplatin Drugs 0.000 claims description 6
- 229960004679 doxorubicin Drugs 0.000 claims description 6
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims description 6
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims description 6
- 229960002949 fluorouracil Drugs 0.000 claims description 6
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims description 6
- 108010044762 nucleolin Proteins 0.000 claims description 6
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims description 6
- 229960001756 oxaliplatin Drugs 0.000 claims description 6
- 150000003904 phospholipids Chemical class 0.000 claims description 6
- 102000020233 phosphotransferase Human genes 0.000 claims description 6
- 108010064556 somatostatin receptor subtype-4 Proteins 0.000 claims description 6
- 150000003408 sphingolipids Chemical class 0.000 claims description 6
- -1 Gemushitabi down Substances 0.000 claims description 5
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 claims description 4
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 claims description 4
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 claims description 4
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 claims description 4
- 239000000232 Lipid Bilayer Substances 0.000 claims description 4
- 125000000524 functional group Chemical group 0.000 claims description 4
- 239000000693 micelle Substances 0.000 claims description 4
- 239000002245 particle Substances 0.000 claims description 4
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims description 4
- 108090001030 Lipoproteins Proteins 0.000 claims description 2
- 102000004895 Lipoproteins Human genes 0.000 claims description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 2
- 229920001400 block copolymer Polymers 0.000 claims description 2
- 150000001841 cholesterols Chemical class 0.000 claims description 2
- 239000000412 dendrimer Substances 0.000 claims description 2
- 229920000736 dendritic polymer Polymers 0.000 claims description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims description 2
- 239000010931 gold Substances 0.000 claims description 2
- 229910052737 gold Inorganic materials 0.000 claims description 2
- 239000002353 niosome Substances 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- 229920000575 polymersome Polymers 0.000 claims description 2
- 239000002096 quantum dot Substances 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000000178 monomer Substances 0.000 description 4
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 3
- 229960005277 gemcitabine Drugs 0.000 description 3
- 238000003384 imaging method Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000002059 diagnostic imaging Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38620110P | 2010-09-24 | 2010-09-24 | |
| US61/386,201 | 2010-09-24 | ||
| PCT/US2011/052856 WO2012040524A1 (en) | 2010-09-24 | 2011-09-23 | Aptamer conjugates for targeting of therapeutic and/or diagnostic nanocarriers |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015210354A Division JP2016026205A (ja) | 2010-09-24 | 2015-10-27 | 治療ナノキャリアおよび／または診断ナノキャリアのターゲティングのためのアプタマーコンジュゲート |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013538829A JP2013538829A (ja) | 2013-10-17 |
| JP2013538829A5 true JP2013538829A5 (enExample) | 2014-10-09 |
| JP5927194B2 JP5927194B2 (ja) | 2016-06-01 |
Family
ID=44774137
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013530333A Expired - Fee Related JP5927194B2 (ja) | 2010-09-24 | 2011-09-23 | 治療ナノキャリアおよび／または診断ナノキャリアのターゲティングのためのアプタマーコンジュゲート |
| JP2015210354A Pending JP2016026205A (ja) | 2010-09-24 | 2015-10-27 | 治療ナノキャリアおよび／または診断ナノキャリアのターゲティングのためのアプタマーコンジュゲート |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015210354A Pending JP2016026205A (ja) | 2010-09-24 | 2015-10-27 | 治療ナノキャリアおよび／または診断ナノキャリアのターゲティングのためのアプタマーコンジュゲート |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20120082616A1 (enExample) |
| EP (1) | EP2618846A1 (enExample) |
| JP (2) | JP5927194B2 (enExample) |
| KR (1) | KR20130136983A (enExample) |
| CN (1) | CN103269722A (enExample) |
| CA (1) | CA2811601A1 (enExample) |
| IL (1) | IL225414A0 (enExample) |
| WO (1) | WO2012040524A1 (enExample) |
Families Citing this family (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2009001636A (es) * | 2006-08-16 | 2009-02-23 | Novartis Ag | Metodo para elaborar dispersiones solidas de compuestos terapeuticos altamente cristalinos. |
| KR101525132B1 (ko) * | 2008-10-08 | 2015-06-02 | 포항공과대학교 산학협력단 | Ｘ 선용 조영제 캡슐 및 이의 제조방법 |
| US20100233270A1 (en) | 2009-01-08 | 2010-09-16 | Northwestern University | Delivery of Oligonucleotide-Functionalized Nanoparticles |
| US9867886B2 (en) * | 2011-04-15 | 2018-01-16 | Snu R&Db Foundation | Complex in which anti-cotinine antibody is bound to conjugate of cotinine and binding substance, and use thereof |
| JP2014528411A (ja) * | 2011-09-30 | 2014-10-27 | マリンクロッド エルエルシー | 相補的オリゴヌクレオチドリンカーを用いる標的化ナノ粒子の遠隔アセンブリ |
| RU2493848C1 (ru) * | 2012-06-14 | 2013-09-27 | Геннадий Петрович Власов | Биодеградируемый полимерный носитель для доставки противоопухолевого лекарственного средства (варианты) |
| EP2971010B1 (en) | 2013-03-14 | 2020-06-10 | ModernaTX, Inc. | Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions |
| EP3041938A1 (en) | 2013-09-03 | 2016-07-13 | Moderna Therapeutics, Inc. | Circular polynucleotides |
| EP3041934A1 (en) | 2013-09-03 | 2016-07-13 | Moderna Therapeutics, Inc. | Chimeric polynucleotides |
| WO2015051214A1 (en) | 2013-10-03 | 2015-04-09 | Moderna Therapeutics, Inc. | Polynucleotides encoding low density lipoprotein receptor |
| CN105939699B (zh) | 2013-12-03 | 2020-10-02 | 西北大学 | 脂质体颗粒、制备所述脂质体颗粒的方法以及其用途 |
| TR201908550T4 (tr) | 2014-06-04 | 2019-07-22 | Exicure Inc | Profilaktik veya terapötik uygulamalar için lipozomal sferik nükleik asitler tarafından immün modülatörlerin çok değerlikli teslimi. |
| CA2955250A1 (en) | 2014-07-16 | 2016-01-21 | Moderna Therapeutics, Inc. | Chimeric polynucleotides |
| US20170210788A1 (en) | 2014-07-23 | 2017-07-27 | Modernatx, Inc. | Modified polynucleotides for the production of intrabodies |
| JP6595232B2 (ja) | 2015-07-02 | 2019-10-23 | ソニー・オリンパスメディカルソリューションズ株式会社 | 内視鏡用撮像装置、内視鏡装置、及び内視鏡用ケーブル |
| KR101704379B1 (ko) * | 2015-10-27 | 2017-02-08 | (주)알테오젠 | 항체-약물 접합체 및 그 제조방법 |
| CN108697815A (zh) * | 2016-02-10 | 2018-10-23 | 辉瑞公司 | 具有egfr配体的治疗性纳米颗粒及其制备和使用方法 |
| KR101856838B1 (ko) * | 2016-02-17 | 2018-06-19 | 이희정 | 베타-아밀로이드 올리고머에 대한 압타머 및 이의 용도 |
| US11866700B2 (en) * | 2016-05-06 | 2024-01-09 | Exicure Operating Company | Liposomal spherical nucleic acid (SNA) constructs presenting antisense oligonucleotides (ASO) for specific knockdown of interleukin 17 receptor mRNA |
| KR102015524B1 (ko) * | 2016-12-26 | 2019-08-29 | 인터올리고 주식회사 | 압타머-약물 콘쥬게이트 및 그 용도 |
| WO2018201090A1 (en) | 2017-04-28 | 2018-11-01 | Exicure, Inc. | Synthesis of spherical nucleic acids using lipophilic moieties |
| US11421011B2 (en) | 2017-05-18 | 2022-08-23 | Modernatx, Inc. | Polynucleotides encoding tethered interleukin-12 (IL12) polypeptides and uses thereof |
| ES2952779T3 (es) | 2017-05-18 | 2023-11-06 | Modernatx Inc | ARN mensajero modificado que comprende elementos de ARN funcionales |
| US20200268666A1 (en) | 2017-06-14 | 2020-08-27 | Modernatx, Inc. | Polynucleotides encoding coagulation factor viii |
| CN116650678A (zh) * | 2017-07-07 | 2023-08-29 | 德雷克塞尔大学 | 电压活化的治疗、诊断和/或诊疗构建体 |
| CN107998080A (zh) * | 2017-11-21 | 2018-05-08 | 东南大学 | 一种偶联抗体的主动靶向载药长循环脂质体及其制备方法 |
| EP3714047A2 (en) | 2017-11-22 | 2020-09-30 | ModernaTX, Inc. | Polynucleotides encoding phenylalanine hydroxylase for the treatment of phenylketonuria |
| MA50802A (fr) | 2017-11-22 | 2020-09-30 | Modernatx Inc | Polynucléotides codant pour des sous-unités alpha et bêta de propionyl-coa carboxylase pour le traitement de l'acidémie propionique |
| JP7423522B2 (ja) | 2017-11-22 | 2024-01-29 | モダーナティエックス・インコーポレイテッド | 尿素サイクル異常症の治療のためのオルニチントランスカルバミラーゼをコードするポリヌクレオチド |
| WO2019136241A1 (en) | 2018-01-05 | 2019-07-11 | Modernatx, Inc. | Polynucleotides encoding anti-chikungunya virus antibodies |
| US11007211B2 (en) * | 2018-01-07 | 2021-05-18 | City Of Hope | CCR7 aptamers and uses thereof |
| CN110536680B (zh) * | 2018-01-22 | 2021-02-26 | 北京茵诺医药科技有限公司 | 用于靶向活化cd44分子的树枝状聚合物纳米载体递送系统、其制备方法和用途 |
| KR101977532B1 (ko) * | 2018-03-09 | 2019-05-10 | 연세대학교 원주산학협력단 | 약물, 양자점 및 표적화제를 포함하는 나노 마이셀 및 이의 용도 |
| WO2019226650A1 (en) | 2018-05-23 | 2019-11-28 | Modernatx, Inc. | Delivery of dna |
| US20220184185A1 (en) | 2018-07-25 | 2022-06-16 | Modernatx, Inc. | Mrna based enzyme replacement therapy combined with a pharmacological chaperone for the treatment of lysosomal storage disorders |
| MA53545A (fr) | 2018-09-02 | 2021-07-14 | Modernatx Inc | Polynucléotides codant pour l'acyl-coa déshydrogénase à très longue chaîne pour le traitement de l'insuffisance en acyl-coa déshydrogénase à très longue chaîne |
| MA53608A (fr) | 2018-09-13 | 2021-07-21 | Modernatx Inc | Polynucléotides codant pour les sous-unités e1-alpha, e1-beta et e2 du complexe alpha-cétoacide déshydrogénase à chaîne ramifiée pour le traitement de la leucinose |
| MX2021003015A (es) | 2018-09-13 | 2021-07-15 | Modernatx Inc | Polinucleotidos que codifican glucosa-6-fosfatasa para el tratamiento de la glucogenosis. |
| EP3850102A1 (en) | 2018-09-14 | 2021-07-21 | ModernaTX, Inc. | Polynucleotides encoding uridine diphosphate glycosyltransferase 1 family, polypeptide a1 for the treatment of crigler-najjar syndrome |
| EP3856233A1 (en) | 2018-09-27 | 2021-08-04 | Modernatx, Inc. | Polynucleotides encoding arginase 1 for the treatment of arginase deficiency |
| CN114375190A (zh) | 2019-05-08 | 2022-04-19 | 阿斯利康(瑞典)有限公司 | 用于皮肤和伤口的组合物及其使用方法 |
| CA3141783A1 (en) * | 2019-05-31 | 2020-12-03 | Shin Nippon Biomedical Laboratories, Ltd. | Mass spectrometry method using chromatography-mass spectrometry device |
| CN110787149A (zh) * | 2019-11-12 | 2020-02-14 | 深圳碳十四科技创新有限公司 | 双壳层纳米粒子及其制备方法 |
| CA3184474A1 (en) | 2020-06-01 | 2021-12-09 | Modernatx, Inc. | Phenylalanine hydroxylase variants and uses thereof |
| EP4199906A1 (en) * | 2020-08-20 | 2023-06-28 | Bionanosim (BNS) Ltd | Lipid delivery systems for delivery of oxaliplatin palmitate acetate |
| WO2022104131A1 (en) | 2020-11-13 | 2022-05-19 | Modernatx, Inc. | Polynucleotides encoding cystic fibrosis transmembrane conductance regulator for the treatment of cystic fibrosis |
| WO2022204390A1 (en) | 2021-03-24 | 2022-09-29 | Modernatx, Inc. | Lipid nanoparticles containing polynucleotides encoding phenylalanine hydroxylase and uses thereof |
| WO2022204380A1 (en) | 2021-03-24 | 2022-09-29 | Modernatx, Inc. | Lipid nanoparticles containing polynucleotides encoding propionyl-coa carboxylase alpha and beta subunits and uses thereof |
| WO2022204369A1 (en) | 2021-03-24 | 2022-09-29 | Modernatx, Inc. | Polynucleotides encoding methylmalonyl-coa mutase for the treatment of methylmalonic acidemia |
| EP4314260A1 (en) | 2021-03-24 | 2024-02-07 | Modernatx, Inc. | Lipid nanoparticles and polynucleotides encoding ornithine transcarbamylase for the treatment of ornithine transcarbamylase deficiency |
| US20240207374A1 (en) | 2021-03-24 | 2024-06-27 | Modernatx, Inc. | Lipid nanoparticles containing polynucleotides encoding glucose-6-phosphatase and uses thereof |
| US20240384277A1 (en) | 2021-06-15 | 2024-11-21 | Modernatx, Inc. | Engineered polynucleotides for cell-type or microenvironment-specific expression |
| WO2022271776A1 (en) | 2021-06-22 | 2022-12-29 | Modernatx, Inc. | Polynucleotides encoding uridine diphosphate glycosyltransferase 1 family, polypeptide a1 for the treatment of crigler-najjar syndrome |
| US20250017867A1 (en) | 2021-10-01 | 2025-01-16 | Modernatx, Inc. | Polynucleotides encoding relaxin for the treatment of fibrosis and/or cardiovascular disease |
| EP4499153A2 (en) | 2022-03-25 | 2025-02-05 | ModernaTX, Inc. | Polynucleotides encoding fanconi anemia, complementation group proteins for the treatment of fanconi anemia |
| CA3256834A1 (en) * | 2022-05-05 | 2023-11-09 | Aion Healthspan Inc | STEM CELL AND NANOMATERIAL COMPOSITIONS AND METHODS OF USE |
| WO2024026254A1 (en) | 2022-07-26 | 2024-02-01 | Modernatx, Inc. | Engineered polynucleotides for temporal control of expression |
| WO2024130158A1 (en) | 2022-12-16 | 2024-06-20 | Modernatx, Inc. | Lipid nanoparticles and polynucleotides encoding extended serum half-life interleukin-22 for the treatment of metabolic disease |
| WO2024182301A2 (en) | 2023-02-27 | 2024-09-06 | Modernatx, Inc. | Lipid nanoparticles and polynucleotides encoding galactose-1-phosphate uridylyltransferase (galt) for the treatment of galactosemia |
| WO2024197033A1 (en) | 2023-03-21 | 2024-09-26 | Modernatx, Inc. | Polynucleotides encoding relaxin for the treatment of heart failure |
| AU2024265267A1 (en) | 2023-05-03 | 2025-11-20 | Modernatx, Inc. | Polynucleotides encoding cystic fibrosis transmembrane conductance regulator for the treatment of cystic fibrosis |
| WO2025072482A1 (en) | 2023-09-27 | 2025-04-03 | Modernatx, Inc. | Immunoglobulin a protease polypeptides, polynucleotides, and uses thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5567588A (en) | 1990-06-11 | 1996-10-22 | University Research Corporation | Systematic evolution of ligands by exponential enrichment: Solution SELEX |
| US5646261A (en) * | 1992-01-22 | 1997-07-08 | Hoechst Aktiengesellschaft | 3'-derivatized oligonucleotide analogs with non-nucleotidic groupings, their preparation and use |
| DE122006000029I1 (de) * | 1996-10-25 | 2006-10-19 | Gilead Sciences Inc | Gefaesszellen Wachstumsfaktor (vegf) nukleins{ureligand-Komplexe |
| DE10049074A1 (de) | 2000-10-02 | 2002-04-18 | Andreas Kage | Verfahren zur Selektion hochaffin an ein Target bindender Nukleinsäuren |
| WO2006078646A2 (en) | 2005-01-18 | 2006-07-27 | Caltagirone Gaetano T | A class of supramolecular drug molecules and methods of identification and use thereof |
-
2011
- 2011-09-23 CN CN2011800566733A patent/CN103269722A/zh active Pending
- 2011-09-23 CA CA2811601A patent/CA2811601A1/en not_active Abandoned
- 2011-09-23 WO PCT/US2011/052856 patent/WO2012040524A1/en not_active Ceased
- 2011-09-23 EP EP11767527.2A patent/EP2618846A1/en not_active Withdrawn
- 2011-09-23 KR KR1020137007244A patent/KR20130136983A/ko not_active Withdrawn
- 2011-09-23 US US13/241,368 patent/US20120082616A1/en not_active Abandoned
- 2011-09-23 JP JP2013530333A patent/JP5927194B2/ja not_active Expired - Fee Related
-
2013
- 2013-03-21 IL IL225414A patent/IL225414A0/en unknown
-
2015
- 2015-10-27 JP JP2015210354A patent/JP2016026205A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013538829A5 (enExample) | ||
| He et al. | Aptamer-based targeted drug delivery systems: current potential and challenges | |
| US8889657B2 (en) | Nanoparticle PEG modification with H-phosphonates | |
| JP5927194B2 (ja) | 治療ナノキャリアおよび／または診断ナノキャリアのターゲティングのためのアプタマーコンジュゲート | |
| Allen et al. | Pharmacokinetics and pharmacodynamics of lipidic nano-particles in cancer | |
| CN104023793B (zh) | 用于治疗癌症的联合脂质体组合物 | |
| Dai et al. | Combined mTOR inhibitor rapamycin and doxorubicin-loaded cyclic octapeptide modified liposomes for targeting integrin α3 in triple-negative breast cancer | |
| Mussi et al. | Recent trends in the use of lipidic nanoparticles as pharmaceutical carriers for cancer therapy and diagnostics | |
| Jain et al. | Multipronged, strategic delivery of paclitaxel-topotecan using engineered liposomes to ovarian cancer | |
| JP2014527071A5 (enExample) | ||
| JP2014528411A5 (enExample) | ||
| Karpuz et al. | Design and in vitro evaluation of folate-targeted, co-drug encapsulated theranostic liposomes for non-small cell lung cancer | |
| JP2015502946A5 (enExample) | ||
| Van Herck et al. | Nanomedicine-mediated alteration of the pharmacokinetic profile of small molecule cancer immunotherapeutics | |
| US20140234217A1 (en) | Remote assembly of targeted nanoparticles using complementary oligonucleotide linkers | |
| Yu et al. | Nanoparticles for the treatment of bone metastasis in breast cancer: recent advances and challenges | |
| Yang et al. | Chitosan hybrid nanoparticles as a theranostic platform for targeted doxorubicin/VEGF shRNA co-delivery and dual-modality fluorescence imaging | |
| EP3258913A1 (en) | Modified docetaxel liposome formulations and uses thereof | |
| TWI760319B (zh) | 乳癌治療 | |
| Grewal et al. | New era of nanoparticles facilitated co-delivery in cancer therapy: two heads are better than one | |
| Stanczyk et al. | Dendrimers in therapy for breast and colorectal cancer | |
| JP2014525459A5 (enExample) | ||
| Zhu et al. | Current progresses of functional nanomaterials for imaging diagnosis and treatment of melanoma | |
| Kim et al. | Image-guided nanoparticle-based siRNA delivery for cancer therapy | |
| CA2845851A1 (en) | Remote assembly of targeted nanoparticles using h-phosphonate-ene/-yne hydrophosphonylation reactions |